Please use this identifier to cite or link to this item: https://doi.org/10.2122/gbc.2012.0251
Title: Trametinib plus dabrafenib: Targeting RAS-MAPK pathway for BRAF V600-mutant melanoma
Authors: Ku, C.-S. 
Issue Date: Oct-2012
Source: Ku, C.-S. (2012-10). Trametinib plus dabrafenib: Targeting RAS-MAPK pathway for BRAF V600-mutant melanoma. Gastric and Breast Cancer 11 (4) : 208-210. ScholarBank@NUS Repository. https://doi.org/10.2122/gbc.2012.0251
Abstract: Genetic and epigenetic changes and signalling pathways activation drive carcinogenesis, tumor growth and metastasis. One of several signalling pathways involved in ∼ 20% of cancers is the RAF-MEK-ERK pathway that is activated through RAS oncoproteins or mutations in these genes [1]. In 66% of melanomas and in lower frequency for other cancer types, activating mutations in BRAF have been found. Despite progression-free survival and overall survival benefit with vemurafenib and dabrafenib that are BRAF and MEK inhibitors of BRAFV600-mutant advanced melanomas respectively [2,3], resistance occurs in more than 50% of patients. In a more recent phase 1 and 2 study, the BRAF-MEK complex of dabrafenib plus trametinib inhibitors has been evaluated for metastatic melanoma patients with BRAF V600 mutations [4]. Can this combined treatment decrease resistance for improving survival of these patients?
Source Title: Gastric and Breast Cancer
URI: http://scholarbank.nus.edu.sg/handle/10635/116896
ISSN: 11097655
DOI: 10.2122/gbc.2012.0251
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

81
checked on Feb 15, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.